Patents Assigned to Altergon S.A.
-
Publication number: 20240000955Abstract: Disclosed are soluble polyelectrolyte complexes of polymeric biguanidine antimicrobial, such as polyhexamethylene biguanide or polyaminopropyl biguanide, with glycosaminoglycans, such as hyaluronic acid, chondroitin or chondroitin sulphate and derivatives thereof, and their use as active ingredients of pharmaceutical compositions or medical devices.Type: ApplicationFiled: November 29, 2021Publication date: January 4, 2024Applicant: Altergon S.A.Inventors: Chiara Schiraldi, Mario De Rosa, Tiziano Fossati
-
Patent number: 11717486Abstract: New soft capsules are described having within them a fill which contains thyroid hormones such as thyroxine T4 or triiodothyronine T3) and a high amylose-starch, optionally associated with vegetable hydrocolloids and/or glycerol. Compared to traditional capsules, these capsules have a strong and unexpected increase in the stability of T4 or T3 during storage.Type: GrantFiled: March 6, 2019Date of Patent: August 8, 2023Assignee: ALTERGON S.A.Inventors: Simone Carucci, Maurizio Marchiorri, Marco Pontiggia, Tiziano Fossati
-
Publication number: 20230074099Abstract: Disclosed are injectable dermo-aesthetic formulations comprising aqueous solutions of at least one unmodified high-molecular-weight linear hyaluronic acid or hyaluronate and at least one unmodified low-molecular-weight linear hyaluronic acid or hyaluronate or non-sulphated chondroitin. The compositions according to the invention are useful as fillers with an excellent safety profile, adequate residence time at the site of application, and limited extrusion force.Type: ApplicationFiled: December 17, 2020Publication date: March 9, 2023Applicant: Altergon S.A.Inventor: Andrea Maria Giori
-
Publication number: 20230019560Abstract: Disclosed are intra-articular compositions comprising at least one low-molecular-weight linear hyaluronic acid or hyaluronate and at least one high-molecular-weight linear hyaluronic acid or hyaluronate, said compositions being characterised by a dynamic viscosity ranging between 10 and 60 Pa*s (at 0.01 s-1), a crossover frequency ranging between 1 and 10 rad/s, and a value of the viscous and elastic moduli at the crossover frequency ranging between 20 and 110 Pa.Type: ApplicationFiled: December 17, 2020Publication date: January 19, 2023Applicant: Altergon S.A.Inventors: Marta Cicognani, Andrea Maria Giori, Gabriele Vecchi
-
Publication number: 20220233745Abstract: Disclosed is a process for the preparation of hydrogels consisting of crosslinked glycosaminoglycans, which comprises: a) reacting at least one hybrid cooperative complex obtained by heating aqueous solutions of low- and high-molecular-weight glycosaminoglycans at 80-160° C. with a diepoxide as crosslinker in a ratio with the complex ranging between 0.1 and 1 equivalents, preferably between 0.2 and 0.4 equivalents, the concentration by weight of the complex in the solution ranging between 1% and 15%, preferably between 2% and 10%; b) purifying by dialysis, ultrafiltration and diafiltration.Type: ApplicationFiled: April 14, 2022Publication date: July 28, 2022Applicant: Altergon S.A.Inventors: Nicola Solimando, Maurizio Pagliuca
-
Publication number: 20220118155Abstract: The present invention relates to compositions based on: (a) a glycosaminoglycan or mixtures thereof; (b) one or more tocopherols, tocotrienols and mixtures thereof; and (c) a selected stabilizer. The composition is a solution, with the agents not chemically bound with each other. The component (a) can be hyaluronic acid (HA) or a salt thereof; the component (b) can be a polyether clathrate a cyclodextrin, or a combination of a fatty acid with an emulsifier; the component (c) can be ?-tocopherols, ?-tocopherols, ?-tocopherols, ?-tocopherols; ?-tocotrienols, ?-tocotrienols, ?-tocotrienols, ?-tocotrienols. Preferably component (c) is vitamin E. The agents strongly cooperate to provide enhanced and more stable viscoelastic properties, resulting in a product with higher resistance to thermal treatments like e.g. heat-sterilization, autoclaving, etc. The present compositions, optionally loaded with pharmaceutically and/or cosmetically active agents, are advantageously used in medical or cosmetic methods.Type: ApplicationFiled: July 24, 2019Publication date: April 21, 2022Applicant: ALTERGON S.A.Inventors: Assunta BORZACCHIELLO, Maurizio PAGLIUCA, Nicola SOLIMANDO, Luigi NICOLAIS
-
Patent number: 11304910Abstract: Disclosed are soft gelatin capsules comprising a gelatin shell, a plasticiser, water, and optionally a calcium salt and a filling containing a dispersed or solubilised medicament comprising gelatin with gelling power, hydrolysed gelatin, glycerol, water, pectin and gellan gum. The formulations according to the invention allow gradual release of the active ingredient, regardless of pH.Type: GrantFiled: November 25, 2016Date of Patent: April 19, 2022Assignee: Altergon S.A.Inventors: Simone Carucci, Maurizio Marchiorri, Marco Pontiggia, Tiziano Fossati
-
Publication number: 20220088121Abstract: Disclosed are pharmaceutical or nutraceutical compositions comprising the peptide having the sequence NMYLPPVPPP PVVPTF or extracts containing it, in admixture with suitable excipients.Type: ApplicationFiled: January 7, 2020Publication date: March 24, 2022Applicants: Altergon S.A., FONDAZIONE FORESTA - ONLUSInventors: Carlo Foresta, Luca De Toni, Andrea Di Nisio, Maurizio De Rocco Ponce, Andrea Giori
-
Publication number: 20210386776Abstract: Disclosed are ophthalmic formulations which use complexes called L/H-HA, obtainable by subjecting at least two fractions of hyaluronic acids and/or other glycosaminoglycans with different molecular weights to an appropriate heat cycle.Type: ApplicationFiled: August 27, 2021Publication date: December 16, 2021Applicant: Altergon S.A.Inventors: Mario De Rosa, Chiara Schiraldi
-
Patent number: 11090271Abstract: New soft gelatin capsules highly protected against the degradation of the active ingredient contained therein and highly resistant to hydration are described. The capsular wall is characterized by containing hydroxypropyl beta cyclodextrin in low quantity with respect to the weight of the wall and sub-stoichiometric with respect to that necessary for complexing the drug contained within the capsule. The new capsules are storage-stable, avoid the development of active ingredient by-products and maintain a high weight constancy, i.e. low hygroscopy.Type: GrantFiled: February 9, 2018Date of Patent: August 17, 2021Assignee: ALTERGON S.A.Inventors: Simone Carucci, Maurizio Marchiorri, Marco Pontiggia, Tiziano Fossati
-
Patent number: 10927143Abstract: The invention relates to a process for decontaminating a biological material by partitioning and inactivation techniques. The process includes the formation of a three-layer liquid system (a-b-c), where the layers are placed one onto the other and are different from each other in density and/or miscibility properties. The upper layer (a) has an aqueous solution of the biological material to decontaminate; the lower layer (c) has the solution inactivating viruses, prions or bacteria; the intermediate layer (b), interposed between the upper and lower layers, separates and protects the biological material from the inactivating solution which has an organic solvent or a mixture of more such solvents, immiscible at least with the upper layer. Moreover, the invention provides specific indications about the density difference between the layers in order to preserve system stability and, at the same time, protect the efficiency of decontamination and the biological activity of the material undergoing decontamination.Type: GrantFiled: July 25, 2017Date of Patent: February 23, 2021Assignee: ALTERGON S.A.Inventors: Costantino Cozzari, Luca Angiolini
-
Patent number: 10905669Abstract: The present invention provides for a method of improving the release of non-steroidal anti-inflammatory drugs (NSAIDs) from a plaster or bandage comprising an adhesive layer with a pharmaceutically acceptable NSAID together with heparin or a heparinoid. The invention also provides for methods of reducing muscle hyperalgesia in subjects without spontaneous pain.Type: GrantFiled: February 20, 2015Date of Patent: February 2, 2021Assignee: ALTERGON S.A.Inventors: Valeria Frangione, Arturo Lanzarotti
-
Publication number: 20200375909Abstract: New soft capsules are described having within them a fill which contains thyroid hormones such as thyroxine T4 or triiodothyronine T3) and a high amylose-starch, optionally associated with vegetable hydrocolloids and/or glycerol. Compared to traditional capsules, these capsules have a strong and unexpected increase in the stability of T4 or T3 during storage.Type: ApplicationFiled: March 6, 2019Publication date: December 3, 2020Applicant: ALTERGON S.A.Inventors: Simone CARUCCI, Maurizio MARCHIORRI, Marco PONTIGGIA, Tiziano FOSSATI
-
Patent number: 10842883Abstract: The present invention concerns the preparation and the therapeutic use of aqueous solutions of Progesterone or Testosterone, complexed with hydroxypropyl-?-cyclodextrin (HP?CD) that are suitable for oral administration. The solutions are characterised by a specific molar ratio between HP?CD and the hormones such as to ensure high hormone plasma levels, following oral administration, thanks to the optimisation of their solubility, permeability, metabolic stability and ultimately, bioavailability. The formulation object of the present patent makes it possible to achieve effective plasma concentrations following oral administration of lower doses of hormone with respect to oral formulations currently on the market (e.g. Prometrium, Andriol) to the advantage of greater safety and compliance of the patients.Type: GrantFiled: April 7, 2020Date of Patent: November 24, 2020Assignee: ALTERGON S.A.Inventors: Alberto Bernareggi, Nadia Puppini, Alessandro Nencioni
-
Publication number: 20200246297Abstract: Disclosed are novel formulations of oral tetraiodothyronine (T4), characterised by the formation in aqueous media of soluble, bioavailable micellar nanoaggregates.Type: ApplicationFiled: April 24, 2020Publication date: August 6, 2020Applicant: Altergon S.A.Inventors: Mario De Rosa, Chiara Schiraldi
-
Publication number: 20200230258Abstract: The present invention concerns the preparation and the therapeutic use of aqueous solutions of Progesterone or Testosterone, complexed with hydroxypropyl-?-cyclodextrin (HP?CD) that are suitable for oral administration. The solutions are characterised by a specific molar ratio between HP?CD and the hormones such as to ensure high hormone plasma levels, following oral administration, thanks to the optimisation of their solubility, permeability, metabolic stability and ultimately, bioavailability. The formulation object of the present patent makes it possible to achieve effective plasma concentrations following oral administration of lower doses of hormone with respect to oral formulations currently on the market (e.g. Prometrium, Andriol) to the advantage of greater safety and compliance of the patients.Type: ApplicationFiled: April 7, 2020Publication date: July 23, 2020Applicant: ALTERGON S.A.Inventors: Alberto BERNAREGGI, Nadia PUPPINI, Alessandro NENCIONI
-
Patent number: 10675270Abstract: The present invention relates to the use of chondroitin as a transdermal carrier and slow-release system for active ingredients in pharmaceutical and cosmeceutical compositions.Type: GrantFiled: September 7, 2018Date of Patent: June 9, 2020Assignee: Altergon S.A.Inventors: Mario De Rosa, Chiara Schiraldi
-
Patent number: 10646586Abstract: The present invention concerns the preparation and the therapeutic use of aqueous solutions of Progesterone or Testosterone, complexed with hydroxypropyl-3-cyclodextrin (HP?CD) that are suitable for oral administration. The solutions are characterised by a specific molar ratio between HP?CD and the hormones such as to ensure high hormone plasma levels, following oral administration, thanks to the optimisation of their solubility, permeability, metabolic stability and ultimately, bio availability. The formulation object of the present patent makes it possible to achieve effective plasma concentrations following oral administration of lower doses of hormone with respect to oral formulations currently on the market (e.g. Prometrium, Andriol) to the advantage of greater safety and compliance of the patients.Type: GrantFiled: November 22, 2013Date of Patent: May 12, 2020Assignee: ALTERGON S.A.Inventors: Alberto Bernareggi, Nadia Puppini, Alessandro Nencioni
-
Publication number: 20190374475Abstract: New soft gelatin capsules highly protected against the degradation of the active ingredient contained therein and highly resistant to hydration are described. The capsular wall is characterized by containing hydroxypropyl beta cyclodextrin in low quantity with respect to the weight of the wall and sub-stoichiometric with respect to that necessary for complexing the drug contained within the capsule. The new capsules are storage-stable, avoid the development of active ingredient by-products and maintain a high weight constancy, i.e. low hygroscopy.Type: ApplicationFiled: February 9, 2018Publication date: December 12, 2019Applicant: ALTERGON S.A.Inventors: Simone CARUCCI, Maurizio MARCHIORRI, Marco PONTIGGIA, Tiziano FOSSATI
-
Patent number: 10266611Abstract: Describes cooperative hybrid complexes of hyaluronic acid, a simple and economical method for production thereof and use thereof in the area of medicine, cosmetics and food.Type: GrantFiled: December 18, 2015Date of Patent: April 23, 2019Assignee: ALTERGON S.A.Inventors: Mario De Rosa, Antonella D'Agostino, Annalisa La Gatta, Chiara Schiraldi